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INTRODUCTION
Bladder cancer is the sixth most common male cancer world-
wide, and the eighth most common male cancer in Korea.1,2 
Radical cystectomy plus pelvic lymph node dissection (PLND) 
with or without neoadjuvant chemotherapy is a standard treat-
ment option for muscle-invasive bladder cancer (MIBC) with-
out distant metastases. Despite radical cystectomy, MIBC pa-
tients have a poor prognosis, with a 5-year overall survival (OS) 
rate of 50–60%.3-6 Historically, locoregional failure (LRF) after 
radical cystectomy for MIBC was reported in 15–35% of patients 
with pathologic stage T3 disease.4,7 Neoadjuvant and adjuvant 
chemotherapy have been previously attempted to improve clin-
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Purpose: Adjuvant radiotherapy (RT) has been performed to reduce locoregional failure (LRF) following radical cystectomy for lo-
cally advanced bladder cancer; however, its efficacy has not been well established. We analyzed the locoregional recurrence pat-
terns of post-radical cystectomy to identify patients who could benefit from adjuvant RT and determine the optimal target volume.
Materials and Methods: We retrospectively reviewed 160 patients with stage ≥ pT3 bladder cancer who were treated with radical 
cystectomy between January 2006 and December 2015. The impact of pathologic findings, including the stage, lympho-vascular in-
vasion, perineural invasion, margin status, nodal involvement, and the number of nodes removed on failure patterns, was assessed.
Results: Median follow-up period was 27.7 months. LRF was observed in 55 patients (34.3%), 12 of whom presented with syn-
chronous local and regional failures as the first failure. The most common failure pattern was distant metastasis (40%). Among 
LRFs, the most common recurrence site was the cystectomy bed (15.6%). Patients with positive resection margins had a signifi-
cantly higher recurrence rate compared to those without (28% vs. 10%, p=0.004). The pelvic nodal recurrence rate was < 5% in pN0 
patients; the rate of recurrence in the external and common iliac nodes was 12.5% in pN+ patients. The rate of recurrence in the com-
mon iliac nodes was significantly higher in pN2–3 patients than in pN0–1 patients (15.2% vs. 4.4%, p=0.04).
Conclusion: Pelvic RT could be beneficial especially for those with positive resection margins or nodal involvement after radical 
cystectomy. Radiation fields should be optimized based on the patient-specific risk factors.
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ical outcomes; however, treatment failure is still common in 
these patients, and oncologic outcomes remain unaltered.5 The 
Southwest Oncology Group (SWOG)-Intergroup trial reported 
a 5-year actual LRF rate of 32% for MIBC with no benefit from 
methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) 
chemotherapy in terms of locoregional recurrence.4 
Adjuvant pelvic radiotherapy (RT) has been used as local 
treatment to reduce LRF and improve outcomes. In an obser-
vational cohort study involving 15124 locally advanced bladder 
cancer patients from the National Cancer Database (NCDB), 
adjuvant RT was associated with improved OS.8 However, plan-
ning adjuvant RT is challenging in clinical practice, as the bowel 
may replace the cystectomy bed and pelvic cavity, and routine 
RT to the whole pelvis could result in unnecessary gastrointes-
tinal (GI) and genitourinary (GU) toxicities.9 The benefit of ad-
juvant RT is still controversial, and therefore, RT is selectively 
implemented in clinical practice. Only 3.3% of the 15124 pa-
tients in the NCDB received adjuvant RT after cystectomy.8
In the current study, we aimed to identify the patients who 
could benefit from pelvic irradiation by analyzing the patterns 
of failure after radical cystectomy; we also aimed to suggest ap-
propriate target volumes for RT. 
MATERIALS AND METHODS
Study population
Patients who underwent radical cystectomy for MIBC be-
tween January 2006 and December 2015 were identified from 
the database of our institution. In total, 223 consecutive pa-
tients who were diagnosed with pT3 or pT4 stage disease were 
retrospectively reviewed. Those who received neoadjuvant RT 
(n=11) or adjuvant RT (n=3), presented with distant metastasis 
at the initial diagnosis (n=30), or had a history of double prima-
ry cancer (n=4) were excluded. Patients who died periopera-
tively (n=6) or did not undergo follow-up after surgery (n=19) 
were also excluded. Finally, 160 patients were included in this 
study. Pathological stage was assigned in accordance with the 
8th American Joint Committee on Cancer staging system.10 
Pathological analysis of cystectomy specimens was performed 
by an experienced uropathologist at our institute. This retro-
spective study received approval from the Institutional Review 
Board of Yonsei University Severance Hospital (IRB No. 4-2020-
0786).
Treatment
Standard surgical procedures consisted of en bloc radical cys-
tectomy with extended PLND and urinary diversion. The 
boundaries of extended PLND included the nodes between 
aortic bifurcation and common iliac vessels proximally, geni-
tofemoral nerve laterally, circumflex iliac vein distally, and in-
ternal iliac vessels posteriorly.11 However, in some patients, the 
extent of PLND was changed or PLND was not performed dur-
ing operation due to severe adhesion or according to the clini-
cian’s judgment. Gemcitabine (1000 mg/m2 of body-surface 
area) was administered intravenously on days 1, 8, and 15 of 
each cycle. Cisplatin (70 mg/m2) was administered on day 1 
every 28 days. Adjuvant MVAC chemotherapy was adminis-
tered to 20 patients: methotrexate (30 mg/m2 of body-surface 
area) on days 1, 15, and 22; vinblastine (3 mg/m2) on days 2, 
15, and 22; and doxorubicin (30 mg/m2) and cisplatin (70 mg 
mg/m2) on day 2. The doses were adjusted if toxicities occurred. 
Treatment failure
After surgery, regular follow-ups were conducted every 3 
months during the first 2 years and every 6 months over the next 
3 years. Regular follow-up evaluations included computed to-
mography (CT) of the chest and abdomen, magnetic resonance 
imaging (MRI) of the pelvis, and positron emission tomography 
(PET) or PET-CT. All available imaging data were reviewed for 
evidence of treatment failure. Recurrences were documented 
based on the first site identified on imaging studies during the 
entire follow-up period. Patients with two or more local, re-
gional, or distant failures within the same 3-month period were 
considered to have synchronous failure. 
Local failure was defined as a soft tissue recurrence in the 
pelvis according to three predefined subsites: cystectomy bed, 
rectosigmoid region, and “other,” which included subsites that 
were unsuitable for categorization into the first two sites. Re-
gional failure was defined as pelvic lymph node (LN) recurrence 
below the aortic bifurcation. It was categorized according to 
six subsites: common iliac, internal iliac, external iliac, obtura-
tor, pelvic side wall, and presacral LNs. Nodal recurrences ceph-
alad to the aortic bifurcation or within the inguinal area were 
scored as distant metastases. 
Delineation of locoregional failures
We delineated locoregional recurrent tumors based on the vas-
cular structure on reference CT images. As a reference image, 
we used a set of CT images from a patient whose vascular anat-
omy was considered to be the closest to the standard without 
anatomic variation. We depicted the contours of recurrent tu-
mors from 55 patients on axial and coronal views of the refer-
ence CT images. To show common recurrence sites, we drew 
figures overlapping the heatmap of the cumulative histogram 
over a CT image according to cancer stages IIIA and IIIB (Fig. 1). 
Normalization was applied based on the maximum cumulative 
frequency, as there was a difference in cumulative frequency 
between each histogram. Cumulative frequency was represent-
ed by the following colors: blue (20%≤recurrence rate<40%), 
cyan (40–60%), yellow (60–80%), and red (≥80%).
Data and statistical analyses
Univariate and multivariate Cox regression analyses were per-
formed to identify the prognostic factors related to LRF. The 
impact of pathologic findings, including stage, lympho-vascu-
571
Hyun Ju Kim, et al.
https://doi.org/10.3349/ymj.2021.62.7.569
A AB B
lar invasion, perineural invasion, margin status, nodal involve-
ment, number of nodes removed, and the use of adjuvant che-
motherapy, was assessed. LRF-free survival, progression-free 
survival (PFS), and OS were calculated from the date of surgical 
resection to the corresponding events. Kaplan-Meier method 
was used to plot the survival outcomes. For comparison of fail-
ure rates according to risk factors, p values based on the χ2 test, 
Fisher’s exact test, or linear-by-linear association were used. 
All statistical tests were two-sided, with significance defined 
as p value<0.05. All data were analyzed using the IBM SPSS 
software version 23.0 (IBM Corp., Armonk, NY, USA). 
RESULTS
Patient characteristics are listed in Table 1. The median age was 
69 years (range, 35–91 years), and 135 (84.4%) patients were 
male. The most common histopathology was urothelial cell 
carcinoma (96.2%), with the exception of six cases: squamous 
cell carcinoma, two cases; small cell carcinoma, two cases; sig-
net-ring cell carcinoma, one case; and undifferentiated carci-
noma, one case. LN metastasis was pathologically confirmed 
in 64 patients (40%). Resection margin involvement was noted 
in 50 patients (31.3%): R1 resection, 48 patients and R2 resec-
tion, two patients. Positive resection margins were more fre-
quently observed in pT4 patients than in pT3 patients (44% vs. 
25%, p=0.014). Treatment details are also summarized in Table 
1. The median number of LNs removed was 14 [interquartile 
range (IQR), 8–19]. Chemotherapy was administered either 
pre- or postoperatively in 113 patients (70.6%): 24 before sur-
gery, 99 after surgery, and 10 patients before and after surgery. 
Most patients were administered gemcitabine/cisplatin (GC) 
chemotherapy: preoperatively in four, postoperatively in 81, 
and both in five patients. For those who received both neoad-
juvant and adjuvant GC chemotherapy, two or three cycles of 
GC chemotherapy was performed as neoadjuvant treatment 
followed by four to six cycles of adjuvant GC chemotherapy. All 
five patients were treated between 2007 and 2009, and their 
Fig. 1. Volume of loco-regional recurrent tumor in stage IIIA patients (A) and stage IIIB patients (B) on axial CT images. Every CT image of the same level 
is displayed in parallel. All recurrent tumor volumes are delineated based on vessel and bony landmarks. The colors represent cumulative frequencies: 
blue (20%≤recurrence rate<40%), cyan (40–60%), yellow (60–80%), and red (≥80%). 
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treatments were performed at the clinician’s discretion.
Recurrences were observed in 93 patients (58.1%). LRF was 
observed in 55 patients (34.3%), 12 of whom had synchronous 
local and regional failures as the first failure pattern. The me-
dian time to LRF was 6.9 months (IQR: 3.0–12.9). Distant me-
tastasis was the most common pattern of failure, observed in 
64 patients (40%). The median time to distant metastasis was 
8.5 months (IQR: 3.9–18.7). Two or more local, regional, or dis-
tant metastases were observed simultaneously in 33 patients 
(35.5% of all failures). The individual sites of failure according 
to the predefined subsites are summarized in Table 2. As an 
individual failure site, the cystectomy bed was the most com-
mon (25 patients, 15.6%). External and common iliac LN me-
tastases were the most commonly found regional failures (12 
patients, 7.5%). Among distant metastases, bone metastasis as 
a single solid organ metastasis was the most frequent, whereas 
10.6% of patients had disseminated failure.
We investigated pelvic recurrence rates according to the 
pathologic T and N stages and resection margin status. LRF rates 
at each subsite by pathologic stage and resection margin status 
are summarized in Table 3. Regardless of the stage, cystectomy 
bed was the most common failure site among pelvic failures. 
Especially, recurrences in the cystectomy bed were significant-
ly frequent in patients with a positive resection margin (10% 
vs. 28%, p=0.004). 
In terms of nodal recurrences, the rates of recurrence at all 
LN subsites were approximately 5% or below in pN0 patients. 
Among pN+ patients, the rates of recurrence at the external ili-
ac LNs were 11.4% and 13.8% in pT3 and pT4 patients, respec-
tively. Furthermore, the rate of recurrence at the common iliac 
Table 1. Patient Characteristics and Treatment 
Age, yr, median (range) 69 (35–91)
Sex
Male 135 (84.4)
Female   25 (15.6)
Repeated TURB (≥2)
Yes   47 (29.4)
Clinical T stage
cT2   33 (20.6)
cT3 100 (62.5)
cT4   27 (16.9)
Clinical N stage
cN0 123 (76.9)
cN1   16 (10.0)
cN2   20 (12.5)
cN3     1 (0.6)
Histology
Urothelial cell carcinoma 154 (96.2)
Squamous cell carcinoma 2 (1.3)




pT4   52 (32.5)
Pathologic N stage
pN0   96 (60.0)
pN1   18 (11.3)
pN2   39 (24.4)
pN3     7 (4.4)
Pathologic AJCC stage
Stage IIIA 114 (71.2)
Stage IIIB   46 (28.8)
No. of nodes removed
<10   56 (35.0)
10–19   72 (45.0)
20–29   25 (15.6)
≥30     7 (4.4)
LVI
Yes   93 (35.6)
No   57 (58.1)
Unknown   10 (6.3)
PNI
Yes   65 (40.6)
No   85 (53.1)
Unknown   10 (6.3)
Resection margin
R0 110 (68.7)
R1   48 (30.0)
R2     2 (1.3)
Chemotherapy
NACT     4 (2.5)
ACT   99 (61.8)
NACT+ACT   10 (6.3)
No   47 (29.4)
TURB, transurethral resection of the bladder; AJCC, The American Joint 
Committee on Cancer; LVI, lymphovascular invasion; PNI, perineural invasion; 
NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy.
Data are presented as n (%).
Table 2. Patterns of First Recurrence
Site No. of patients % of total patients
Local failure
Cystectomy bed 25 15.6
Rectosigmoid region   8   5.0
Other   8   5.0
Regional failure
Common iliac node 12   7.5
Internal iliac node   6   3.8
External iliac node 12   7.5
Obturator node   4   2.5
Pelvic side wall node   7   4.4
Presacral node   1   0.6
Distant metastasis
Lung   8   5.0
Liver   4   2.5
Bone 11   6.9
Peritoneal seeding   6   3.8
Non-regional LN 17 10.6
Disseminated 17 10.6
Brain   1   0.6
LN, lymph node.
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LNs was remarkably high (20.7%) in pT4N+ patients. To depict 
the recurrence patterns according to nodal stage, we divided 
the patients into two groups: stage IIIA vs. stage IIIB (Table 3). 
The rates of recurrence at the internal iliac, obturator, and pel-
vic side wall LNs were similar between the two groups. Howev-
er, the rate of recurrence at the common iliac LNs was signifi-
cantly high in stage IIIB patients (stage IIIA 4.4% vs. IIIB 15.2%, 
p=0.040). Fig. 1 shows the LRF sites in stage IIIA and IIIB pa-
tients. The extent of external iliac LN recurrence was wider in 
stage IIIB patients than in stage IIIA patients, and the level of re-
currence was more cephalad up to the common iliac LN level. 
As for the resection margin status, the recurrence rates for 
all LN subsites were similar, except those for the internal and 
common iliac LNs (Table 3). Recurrence rates for the internal 
and common iliac LNs were both 10% in patients with positive 
resection margins, but were 0.9% and 6.4%, respectively, in 
patients with negative resection margins. The difference in re-
currence rates for the internal iliac LNs was statistically signifi-
cant between patients with positive and negative resection mar-
gins (p=0.012).
Median follow-up duration was 27.7 months (range, 1.9–
158) for all patients. The 1-, 2-, and 5-year OS rates of the en-
tire cohort were 80.8%, 66.1%, and 46.3%, respectively (Fig. 2). 
The 1-, 2-, and 5-year PFS rates were 60.0%, 41.8%, and 33.9%, 
respectively. Moreover, the median PFS was 17.3 months. The 
1-, 2-, and 5-year LRFS rates were 76.7%, 59.0%, and 40.0%, 
respectively.
The risk factors for LRF are summarized in Table 4. On uni-
variate analysis, sex, history of repeated transurethral resection 
of the bladder (TURB; ≥2), use of adjuvant chemotherapy, LN 
metastases, resection margin status, and perineural invasion 
were significantly associated with LRF. On multivariate analy-
sis, sex [hazard ratio (HR): 2.86; 95% confidence interval (CI): 
1.4–5.9; p=0.004], history of repeated TURB (HR: 2.17; 95% CI: 
1.2–4.0; p=0.015), adjuvant chemotherapy (HR: 0.17; 95% CI: 
0.1–0.3; p<0.001), LN metastases (HR: 2.74; 95% CI: 1.4–5.3; 
p=0.003), and resection margin status (HR: 2.46; 95% CI: 1.4–
4.5; p=0.003) were associated with LRF. On univariate analysis 
of OS, nodal metastasis and adjuvant chemotherapy were sig-
nificantly associated with the outcome. On multivariate anal-
ysis, both nodal metastasis and adjuvant chemotherapy were 
associated with OS. The use of chemotherapy decreased the 
mortality risk (HR: 0.34; 95% CI: 0.21–0.56; p<0.001), while nod-
al metastasis increased the mortality risk (HR: 2.57; 95% CI: 
1.57–4.20; p<0.001). 
Table 3. Loco-Regional Failure Rates by Pathologic Stage and Resection Margin
Stage Stage Resection margin
pT3N- pT3N+ pT4N- pT4N+ p value IIIA IIIB p value Negative Positive p value
Common iliac nodes   4.1   5.7   4.3 20.7 0.014   4.4 15.2   0.040*   6.4 10.0   0.418
Internal iliac nodes   4.1   2.9   0.0   6.9 0.801   3.5   4.3 >0.999*   0.9 10.0     0.012*
External iliac nodes   5.5 11.4   0.0 13.8 0.376   5.3 13.0   0.105*   9.1   4.0   0.257
Obturator nodes   2.7   0.0   0.0   6.9 0.429   2.6   2.2 >0.999*   2.7   2.0 >0.999
Pelvic side wall nodes   4.1   0.0   0.0 13.8 0.119   3.5   6.5   0.411*   3.6   6.0   0.678
Presacral nodes   0.0   0.0   0.0   3.4 0.090   0.0   2.2   0.287*   0.0   2.0   0.312
Cystectomy bed 15.1 20.0 13.0 13.8 0.813 17.5 10.9 0.293 10.0 28.0   0.004
Rectosigmoid region   2.7   5.7   4.3 10.3 0.148   3.5   8.7   0.228*   4.5   6.0   0.696
Other   4.1   2.9 13.0   3.4 0.615   5.3   4.3 >0.999*   5.5   4.0   0.696
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Fig. 2. Kaplan-Meier survival curves for locoregional failure-free survival (A), progression-free survival (B), and overall survival (C).
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DISCUSSION
In this study, we investigated the patterns of failure in stage 
pT3-4 bladder cancer patients who underwent radical cystec-
tomy, focusing primarily on the LRF. Even after radical cystec-
tomy, approximately 60% of the patients experienced treat-
ment failure, 34% of which involved LRF. The most common 
site of LRF was the cystectomy bed, followed by the internal/ex-
ternal iliac LNs. LRF patterns were affected by pathologic risk 
factors, including margin status and pathologic T/N stage. 
There have been several studies which investigated the pel-
vic failure after radical cystectomy in MIBC patients. Reddy, et 
Table 4. Univariate and Multivariate Analyses of Local-Regional Failure
Variable 2-yr LFFS rate (%)
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Sex 2.39 (1.3–4.3) 0.003 2.86 (1.4–5.9)   0.004
Male 65.4
Female 39.6
Age (yr) 1.20 (0.7–2.0)   0.495
<70 63.5
≥70 57.8
Histology 0.42 (0.1–3.0)   0.369
Urothelial carcinoma 60.3
Non-urothelial carcinoma 83.3
Repeated TURB before surgery 2.05 (1.2–3.5)   0.008 2.17 (1.2–4.0)   0.015
<2 66.7
≥2 46.4
Neoadjuvant chemotherapy 1.41 (0.6–3.3)   0.423
No 61.3
Yes 57.0
Adjuvant chemotherapy 0.32 (0.2–0.5) <0.001 0.17 (0.1–0.3) <0.001
No 41.4
Yes 69.4




Pathologic T stage 1.33 (0.8–2.3)   0.293
pT3 62.9
pT4 57.3
LN metastasis 1.79 (1.1–3.0)   0.027 2.74 (1.4–5.3)   0.003
No 68.0
Yes 49.3
No. of LNs removed 1.35 (0.7–2.5)   0.345
<20 64.5
≥20 41.2
Resection margin 2.07 (1.2–3.5)   0.006 2.46 (1.4–4.5)   0.003
Negative 68.1
Positive 45.4
LVI 1.39 (0.8–2.5)   0.266
No 66.2
Yes 59.2
PNI 1.65 (0.9–2.9)   0.077 1.17 (0.6–2.2)   0.614
No 70.6
Yes 52.8
LFFS, local failure-free survival; HR, hazard ratio; CI, confidence interval; TURB, transurethral resection of the bladder; LN, lymph node; LVI, lymphovascular inva-
sion; PNI, perineural invasion.
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al.12 reported 12.8% of LRF among 334 patients who underwent 
radical cystectomy for pT3-4 bladder cancer. Baumann, et al.13 
reported 28% of the 5-year cumulative incidence of pelvic fail-
ure in stage ≥pT3 patients. Our study showed similar or slightly 
higher LRF rates than those from previous studies investigating 
pelvic failure after radical cystectomy in MIBC patients. This 
may be because in our study, failures were detected more fre-
quently due to active imaging evaluation using MRI, PET, or CT 
during follow-up.
Consequently, many authors have tried to identify the risk 
factors related to LRF.6,14-17 Christodouleas, et al.18 proposed risk 
stratification for LRF using the SWOG 8710 cohorts, and report-
ed pT stage, margin status, and the number of dissected lymph 
nodes as prognostic factors. In the study by Reddy, et al.,12 LN 
involvement, pathologic stage, and margin status were signifi-
cant prognostic factors for LRF, similar to our results. 
To reduce pelvic recurrences, several studies have investi-
gated the efficacy of adjuvant RT. Although their results cor-
roborate the use of adjuvant RT for improving locoregional 
control and disease-free survival or OS, the findings are not 
definitive due to their small sample sizes, retrospective study 
design, and heterogeneities.9,19,20 Two historical prospective 
randomized trials from Egypt have demonstrated that postop-
erative RT improved locoregional control and disease-free sur-
vival; the 5-year locoregional control rate was 93% in the post-
operative RT group and 50% in the observational group (p< 
0.05).9,19 However, this study was limited by the fact that only 
20% of the patients had urothelial cell carcinoma, and that an 
old RT technique (2D RT) was used. A large observational co-
hort study by Fisher-Valuck, et al.8 evaluated the effectiveness 
of adjuvant RT using data from the NCDB. They showed that 
adjuvant RT was independently associated with improved OS: 
19.8 months in the RT group vs. 16.9 months in the no-RT group 
(p=0.03). 
Despite of these results, adjuvant RT is still limited in the 
real practice. A major concern inhibiting the use of adjuvant 
RT is toxicity. In the previous studies using outdated RT tech-
niques, GI toxicities were high in up to 37% of patients, making 
adjuvant RT unacceptable.9,21,22 However, recent studies using 
modern RT technique have reported relatively low rates of GI 
or GU toxicity. The results from a French multicenter study re-
ported 5.2% and 9% of Grade ≥3 acute and late GI toxicity, re-
spectively.23 Another study by Zaghloul, et al.24 also reported 7% 
of late Gr 3 GI toxicities. 
Furthermore, an appropriate RT target volume is warranted 
to reduce RT-related toxicities. Baumann, et al.13 reported pel-
vic failure patterns among 442 urothelial cell carcinoma pa-
tients and suggested an appropriate clinical target volume for 
adjuvant RT. They showed that >10% of recurrences occurred 
in the iliac and obturator nodes in stage ≥pT3 patients, and 
that only positive margin status was associated with a signifi-
cant increase in local failure involving the cystectomy bed. 
Based on these results, they recommended that RT should tar-
get at least the iliac and obturator nodes in stage ≥pT3 patients 
with negative margins; coverage of the presacral nodes and cys-
tectomy bed may be necessary for stage ≥pT3 patients with 
positive margins. Reddy, et al.12 also evaluated pelvic failure 
patterns in pT3-4 bladder cancer patients according to risk fac-
tors including pT and pN stages; however, no variations were 
found despite significant differences in clinical outcomes. Our 
results confirmed those of Baumann’s study, and showed that 
the failure site may differ depending on the pT and pN stages 
and resection margin status. 
Our study had some limitations in addition to its retrospec-
tive nature. First, recurrences might have been underestimat-
ed due to the patients’ irregular visiting schedules and small-
sized lesions in the nodal basin that were difficult to recognize 
radiographically. Second, a small number of patients with non-
urothelial cell carcinoma were included in this study; however, 
this may mimic the real clinical situation considering the need 
for adjuvant RT even for such cancers. Third, the evaluation of 
complete surgical resection could not be standardized due to 
the retrospective nature of the study. In the surgical evaluation 
of the primary lesion, recurrence was evaluated based on the 
resection margin, but the extent of LN dissection was not stan-
dardized. Future research should be conducted to evaluate the 
extent of recurrence by standardizing the evaluation of the ex-
tent and completeness of surgical resection.
Our results suggest the potential efficacy of adjuvant RT in 
selective patients who underwent radical cystectomy for stage 
pT3-4 bladder cancer. This study may suggest that it would be 
better to include cystectomy bed in the target volume for ad-
juvant RT, considering the high recurrence rate at this site. In 
patients with pN+ disease, the external iliac LNs are recom-
mended to be included in the target volume, while no nodal 
irradiation may be needed in pN0 patients. Especially, the 
nodal target volume is recommended to extend cephalad up 
to the presacral and common iliac LNs in those with pT4 dis-
ease or positive resection margins. Furthermore, the pelvic 
nodal area may need to be fully covered by RT in pN2-3 pa-
tients who have shown extensive recurrence in the external il-
iac and common iliac LNs.
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